Clinical Trial Update: QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating QL1706 in combination with bevacizumab for unresectable or metastatic MSI-H/dMMR colorectal cancer, with the study curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Avastin (bevacizumab)
• QL1706

Snippet

Sponsor: Qianfoshan Hospital | Conditions: Unresectable Colorectal Cancer, Metastatic Colorectal Cancer (CRC) | Phase 2 | Status: NOT_YET_RECRUITING